Kyoichi Kaira1, Kazuto Nakamura2, Takashi Hirakawa3, Hisao Imai4, Hideyuki Tominaga5, Noboru Oriuchi6, Shushi Nagamori7, Yoshikatsu Kanai7, Norifumi Tsukamoto8, Tetsunari Oyama9, Takayuki Asao10, Takashi Minegishi3. 1. Department of Oncology Clinical Development, Gunma University Graduate School of Medicine Showa-machi, Maebashi, Gunma, Japan ; Department of Oncology Center, Gunma University Hospital Showa-machi, Maebashi, Gunma, Japan. 2. Department of Obstetrics and Gynecology, Gunma University Graduate School of Medicine Showa-machi, Maebashi, Gunma, Japan ; Department of Gynecology, Gunma Prefectural Cancer Center Oota, Gunma, Japan. 3. Department of Obstetrics and Gynecology, Gunma University Graduate School of Medicine Showa-machi, Maebashi, Gunma, Japan. 4. Department of Medicine and Molecular Science, Gunma University Graduate School of Medicine Showa-machi, Maebashi, Gunma, Japan. 5. Advanced Clinical Research Center, Fukushima Medical University Fukushima, Japan. 6. Department of Diagnostic Radiology and Nuclear Medicine, Gunma University Graduate School of Medicine Showa-machi, Maebashi, Gunma, Japan. 7. Division of Bio-system Pharmacology, Graduate School of Medicine, Osaka University Osaka, Japan. 8. Department of Oncology Center, Gunma University Hospital Showa-machi, Maebashi, Gunma, Japan. 9. Department of Diagnostic Pathology, Gunma University Graduate School of Medicine Showa-machi, Maebashi, Gunma, Japan. 10. Department of Oncology Clinical Development, Gunma University Graduate School of Medicine Showa-machi, Maebashi, Gunma, Japan.
Abstract
AIM: Amino acid transporters are essential for the growth, progression and the pathogenesis of various cancers. However, it remains obscure about the clinicopathological significance of L-type amino acid transporter 1 (LAT1) and system ASC amino acid transporter 2 (ASCT2) for patients with human ovarian tumors. The aim of this study is to elucidate the prognostic role of these amino acid transporters in ovarian tumor. METHODS: One-hundred forty-two patients with surgically resected ovarian tumors were analyzed by immunohistochemistry. Expression of LAT1, ASCT2, CD98, Ki-67 and microvessel density (MVD) determined by CD34 were evaluated using specimens of the resected tumors. RESULTS: LAT1 and ASCT2 were positively expressed in 39% and 53%, respectively, of ovarian tumors (n=142) and 50% and 57%, respectively, of epidermal ovarian cancers (n=107). A positive LAT1 expression was closely correlated with the expression for ASCT2 and CD98, and cell proliferation (Ki-67) in ovarian cancer. By multivariate analysis, LAT1 was clarified as a significant independent marker for predicting a poor overall survival (OS). The expression of LAT1 could clearly discriminate between epidermal ovarian cancer and borderline malignancy. The expression level of LAT1 within ovarian cancer cells varied among serous adenocarcinoma, endometrioid adenocarcinoma, clear cell adenocarcinoma and mucinous adenocarcinoma and we found LAT1 expression was higher in clear cell adenocarcinoma than other histological types. CONCLUSIONS: LAT1 is highly expressed in various ovarian tumors and a positive LAT1 expression can serve as a significant independent factor for predicting a poor OS in patients with epidermal ovarian cancer.
AIM: Amino acid transporters are essential for the growth, progression and the pathogenesis of various cancers. However, it remains obscure about the clinicopathological significance of L-type amino acid transporter 1 (LAT1) and system ASC amino acid transporter 2 (ASCT2) for patients with humanovarian tumors. The aim of this study is to elucidate the prognostic role of these amino acid transporters in ovarian tumor. METHODS: One-hundred forty-two patients with surgically resected ovarian tumors were analyzed by immunohistochemistry. Expression of LAT1, ASCT2, CD98, Ki-67 and microvessel density (MVD) determined by CD34 were evaluated using specimens of the resected tumors. RESULTS:LAT1 and ASCT2 were positively expressed in 39% and 53%, respectively, of ovarian tumors (n=142) and 50% and 57%, respectively, of epidermal ovarian cancers (n=107). A positive LAT1 expression was closely correlated with the expression for ASCT2 and CD98, and cell proliferation (Ki-67) in ovarian cancer. By multivariate analysis, LAT1 was clarified as a significant independent marker for predicting a poor overall survival (OS). The expression of LAT1 could clearly discriminate between epidermal ovarian cancer and borderline malignancy. The expression level of LAT1 within ovarian cancer cells varied among serous adenocarcinoma, endometrioid adenocarcinoma, clear cell adenocarcinoma and mucinous adenocarcinoma and we found LAT1 expression was higher in clear cell adenocarcinoma than other histological types. CONCLUSIONS:LAT1 is highly expressed in various ovarian tumors and a positive LAT1 expression can serve as a significant independent factor for predicting a poor OS in patients with epidermal ovarian cancer.
Authors: Rile Li; Mamoun Younes; Anna Frolov; Thomas M Wheeler; Peter Scardino; Makoto Ohori; Gustavo Ayala Journal: Anticancer Res Date: 2003 Jul-Aug Impact factor: 2.480
Authors: K Shimizu; K Kaira; Y Tomizawa; N Sunaga; O Kawashima; N Oriuchi; H Tominaga; S Nagamori; Y Kanai; M Yamada; T Oyama; I Takeyoshi Journal: Br J Cancer Date: 2014-03-06 Impact factor: 7.640
Authors: K Kaira; N Oriuchi; H Imai; K Shimizu; N Yanagitani; N Sunaga; T Hisada; S Tanaka; T Ishizuka; Y Kanai; H Endou; T Nakajima; M Mori Journal: Br J Cancer Date: 2008-02-05 Impact factor: 7.640
Authors: Evan Augustyn; Karissa Finke; Arik A Zur; Logan Hansen; Nathan Heeren; Huan-Chieh Chien; Lawrence Lin; Kathleen M Giacomini; Claire Colas; Avner Schlessinger; Allen A Thomas Journal: Bioorg Med Chem Lett Date: 2016-04-11 Impact factor: 2.823
Authors: Shuntaro Oka; Masaru Kanagawa; Yoshihiro Doi; David M Schuster; Mark M Goodman; Hirokatsu Yoshimura Journal: Int J Mol Sci Date: 2017-04-29 Impact factor: 5.923